10 mg/day of lutein (with 2 mg of zeaxanthin), with food.
Reduces progression to advanced AMD in people at risk.
See the study (large RCT) →Possible improvement in glare and visual fatigue.
View the study (RCT) →⏱ 3 min read
Lutein and zeaxanthin are two closely related yellow-orange carotenoids found in dark leafy greens (spinach, kale, broccoli), egg yolk, and corn, and they share a unique property in the body: they are the only carotenoids that accumulate selectively in the macula of the eye, the small central area of the retina responsible for sharp vision, detail, and reading, where they form the macular pigment that acts as a blue-light filter and as a specific antioxidant for the photoreceptors.
Macular pigment density varies enormously between people and falls with age, especially in smokers, in people with fair skin, and in those who eat little leafy greens; people with low macular pigment have a higher risk of age-related macular degeneration (AMD), the leading cause of legal blindness in people over 65 in developed countries, and supplementation with lutein and zeaxanthin has emerged as one of the few nutritional interventions with serious clinical evidence for protecting long-term vision.
The indication with the best evidence is preventing AMD progression: the AREDS2 trial, published in JAMA in 2013, showed that adding 10 mg of lutein + 2 mg of zeaxanthin to the original AREDS antioxidant cocktail (vitamins C, E, zinc, and copper) significantly reduced progression to advanced AMD in people with intermediate AMD, especially in those with low baseline dietary intake of these carotenoids.
The lutein/zeaxanthin in AREDS2 replaced the beta-carotene of the original cocktail, which had been associated with a higher risk of lung cancer in smokers; the result of this substitution was a safer preventive cocktail and, in the subgroup with low baseline lutein intake, a more effective one: a nutritional intervention with efficacy data comparable to some pharmacological interventions in macular degeneration.
In cataracts, several observational studies have shown inverse associations between lutein/zeaxanthin intake and the risk of cataracts requiring surgery; supplementation trials are more heterogeneous but point to a modest protective effect with long-term use (years); in diabetic retinopathy, there are preliminary data on improvements in contrast sensitivity and reduced macular edema with specific supplementation.
Beyond macular disease, several studies have shown improvements in visual processing speed, contrast sensitivity, and performance on demanding visual tasks with supplementation at 10 mg/day of lutein for 4-12 months in healthy adults, especially in those who spend many hours in front of screens; these effects have been attributed to the improvement in macular pigment, which reduces glare and improves the functional quality of vision.
For global cognition, the data are interesting: several studies have correlated plasma lutein levels with better cognitive function in older adults and, in small trials, supplementation has shown modest improvements in memory and processing speed, suggesting a neuroprotective role that requires confirmation in larger studies.
The doses studied range from 6 to 20 milligrams of lutein daily (with 0.5-4 mg of zeaxanthin), ideally with a fatty meal because absorption depends heavily on the lipid matrix (without fat, less than 25 percent is absorbed); products with standardized free lutein in an oil matrix (softgels) are the best supported clinically and the most effective in terms of bioavailability.
It is one of the supplements with the best safety profile: virtually no adverse effects at the doses studied over years, and no specific contraindications; one harmless cosmetic effect is possible yellowish discoloration of the skin with very high sustained doses (carotenodermia, reversible when the dose is reduced); people who have had recent eye surgery should consult their ophthalmologist before starting supplementation, not because of any known risk but out of the general caution of the postoperative period.
Information, not medical advice. Scientific evidence reflects the quality of the studies.